Abstract: The present disclosure provides antibodies that bind to a gD protein. The present disclosure also discloses a composition comprising an anti-gD protein antibody, a pharmaceutical composition comprising an anti-gD protein antibody and a pharmaceutically acceptable carrier. Also disclosed are a polynucleotide sequence encoding an anti-gD protein, a vector comprising such a polynucleotide, and a cell capable of expressing an anti-gD protein. The present disclosure also provides a method for producing an anti-gD protein antibody, a method for treating HSV-1 and/or HSV-2 infection, and a method for detecting HSV-1 and/or HSV-2.

Abstract: Compositions and methods are provided for treating cancer comprising a composition comprising an oncolytic virus and a targeting moiety on the surface of the virus, wherein the oncolytic virus does not encode or express the targeting moiety within various aspects such compositions and methods can be used to treat a wide variety of cancers (e.g., gastrointestinal cancer, such as esophageal, stomach and colon cancers).

Abstract: Vaccines are provided comprising a recombinant virus which expresses an immunomodulatory protein and a target antigen unrelated to said recombinant virus, and a pharmaceutically acceptable excipient.

Abstract: Recombinant herpes simplex viruses are provided having a modified oncolytic herpes virus genome, wherein the modified herpes virus genome has at least one miRNA target sequence operably linked to a first or to a first and a second copy of an ICP34.5 gene. Also provided are pharmaceutical compositions having such recombinant herpes simplex viruses, as well as methods of using such compositions in the treatment of subjects having cancer.